Therapeutical Approach to Arterial Hypertension - Current State of the Art


Дәйексөз келтіру

Толық мәтін

Аннотация

Arterial hypertension (AH) is recognized as the most common illness within the group of cardiovascular diseases and the most massive chronic non-infectious disease in the world. The number of hypertensive patients worldwide has reached 1.28 billion, contributing to an increase in cardiovascular diseases and premature death globally. The high prevalence of hypertension emphasizes the importance of effectively treating this condition. Elevated blood pressure often leads to lethal complications (heart failure, stroke, renal disorders, etc.) if left untreated. Considering an increase in AH prevalence in the future, a successful therapeutical approach to this disease and its complications is essential. The goal of AH treatment is to maintain normotensive blood pressure through various approaches, including lifestyle changes, a well-balanced diet, increased physical activity, psychoeducation, and, when necessary, pharmacotherapy. The evolving pharmacotherapeutic landscape reflects the progress made in our understanding of hypertension and emphasizes the need for continuous innovation to meet the challenges posed by this prevalent global health concern. The journey toward more effective and tailored treatments for hypertension is ongoing, and the introduction of new medications plays a pivotal role in shaping the future of antihypertensive pharmacotherapy.

Авторлар туралы

Milica Radosavljevic

Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, University of Belgrade

Email: info@benthamscience.net

Danijela Vučević

Faculty of Medicine, Institute of Pathophysiology "Ljubodrag Buba Mihailović", University of Belgrade

Email: info@benthamscience.net

Janko Samardžić

Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade

Email: info@benthamscience.net

Miroslav Radenkovic

Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade

Email: info@benthamscience.net

Tatjana Radosavljević

Faculty of Medicine, Institute of Pathophysiology "Ljubodrag Buba Mihailović", University of Belgrade

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Nenezic, N.; Matunovic, R.; Gudelj, O.; Djuric, I.; Jancic, J.; Samardzic, J. Stress and arterial hypertension - from pathophysiology to pharmacology. Srp. Arh. Celok. Lek., 2021, 149(11-12), 737-740. doi: 10.2298/SARH210323066N
  2. World health organization. hypertension. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension (Accessed 2023-07-13).
  3. Sutters, M. Overview: Systemic hypertension. In: In Current Medical Diagnosis and Treatment; Papadakis, M.; McPhee, S.; Rabow, M.; McQuaid, K., Eds.; McGraw-Hill Education: Columbus, OH, 2023; pp. 443-474.
  4. Vučević, D.; Radak, Đ.; Đorđević, D.; Miletić, M.; Jakovljević, A.; Jorgačević, B.; Vesković, M. Chronic low grade inflammation in aging process as a link on a chain of obesity - related vascular disorders. Medicinska istraživanja, 2018, 52(1), 32-42.
  5. Akhtar, S.; Rosenbaum, S.; Akhtar, S.; Rosenbaum, S. Principles of Geriatric Critical Care; Akhtar, S.; Rosenbaum, S., Eds.; Cambridge University Press: Cambridge, England, 2018. doi: 10.1017/9781316676325
  6. Pauldine, R. Geriatric cardiovascular critical care. In: In Principles of Geriatric Critical Care; Shamsuddin, A.; Stanley, R., Eds.; Cambridge University Press: Cambridge, England, 2018; pp. 81-101. doi: 10.1017/9781316676325.007
  7. Greenland, P.; Peterson, E. The New 2017 ACC/AHA guidelines "up the pressure" on diagnosis and treatment of hypertension. JAMA, 2017, 318(21), 2083-2084. doi: 10.1001/jama.2017.18605 PMID: 29159417
  8. Leung, A.A.; Daskalopoulou, S.S.; Dasgupta, K.; McBrien, K.; Butalia, S.; Zarnke, K.B.; Nerenberg, K.; Harris, K.C.; Nakhla, M.; Cloutier, L.; Gelfer, M.; Lamarre-Cliche, M.; Milot, A.; Bolli, P.; Tremblay, G.; McLean, D.; Tobe, S.W.; Ruzicka, M.; Burns, K.D.; Vallée, M.; Prasad, G.V.R.; Gryn, S.E.; Feldman, R.D.; Selby, P.; Pipe, A.; Schiffrin, E.L.; McFarlane, P.A.; Oh, P.; Hegele, R.A.; Khara, M.; Wilson, T.W.; Penner, S.B.; Burgess, E.; Sivapalan, P.; Herman, R.J.; Bacon, S.L.; Rabkin, S.W.; Gilbert, R.E.; Campbell, T.S.; Grover, S.; Honos, G.; Lindsay, P.; Hill, M.D.; Coutts, S.B.; Gubitz, G.; Campbell, N.R.C.; Moe, G.W.; Howlett, J.G.; Boulanger, J-M.; Prebtani, A.; Kline, G.; Leiter, L.A.; Jones, C.; Côté, A-M.; Woo, V.; Kaczorowski, J.; Trudeau, L.; Tsuyuki, R.T.; Hiremath, S.; Drouin, D.; Lavoie, K.L.; Hamet, P.; Grégoire, J.C.; Lewanczuk, R.; Dresser, G.K.; Sharma, M.; Reid, D.; Lear, S.A.; Moullec, G.; Gupta, M.; Magee, L.A.; Logan, A.G.; Dionne, J.; Fournier, A.; Benoit, G.; Feber, J.; Poirier, L.; Padwal, R.S.; Rabi, D.M.; Rabi, D.M. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can. J. Cardiol., 2017, 33(5), 557-576. doi: 10.1016/j.cjca.2017.03.005 PMID: 28449828
  9. Jin, J. Checking blood pressure at home. JAMA, 2017, 318(3), 310. doi: 10.1001/jama.2017.6670 PMID: 28719694
  10. Melville, S.; Byrd, J.B. Out-of-office blood pressure monitoring in 2018. JAMA, 2018, 320(17), 1805-1806. doi: 10.1001/jama.2018.14865 PMID: 30398589
  11. Myers, M.G. Automated office blood pressure-incorporating sprint into clinical practice. Am. J. Hypertens., 2017, 30(1), 8-11. doi: 10.1093/ajh/hpw086 PMID: 27551025
  12. Byrd, J.B.; Turcu, A.F.; Auchus, R.J. Primary aldosteronism. Circulation, 2018, 138(8), 823-835. doi: 10.1161/CIRCULATIONAHA.118.033597 PMID: 30359120
  13. Bangash, A.; Wajid, F.; Poolacherla, R.; Mim, F.K.; Rutkofsky, I.H. Obstructive sleep apnea and hypertension: A review of the relationship and pathogenic association. Cureus, 2020, 12(5), e8241. doi: 10.7759/cureus.8241 PMID: 32582500
  14. Palmer, B.F.; Clegg, D.J. Blood pressure lowering and potassium intake. J. Hum. Hypertens., 2020, 34(10), 671-672. doi: 10.1038/s41371-020-00396-1 PMID: 32788665
  15. Vučević, D.; Samardžić, J.; Radosavljević, M.; Radak, U.; Jorgačević, B.; Đorđević, D.; Kovačević, S. Unbalanced diet as a cardiometabolic risk factor. Medicinska istraživanja, 2022, 55(1), 23-34.
  16. Radosavljevic, T.; Vučević, D. Binge drinking: pathophysiological and psychological aspects. In: Binge eating and binge drinking: psychological, social and medical implications; Harris, S.B., Ed.; Nova Science: New York, 2013; pp. 201-216.
  17. Virdis, A.; Giannarelli, C.; Fritsch Neves, M.; Taddei, S.; Ghiadoni, L. Cigarette smoking and hypertension. Curr. Pharm. Des., 2010, 16(23), 2518-2525. doi: 10.2174/138161210792062920 PMID: 20550499
  18. Herrmann, S.M.; Textor, S.C. Renovascular hypertension. Endocrinol. Metab. Clin. North Am., 2019, 48(4), 765-778. doi: 10.1016/j.ecl.2019.08.007 PMID: 31655775
  19. Morgan, T.; Anderson, A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J. Clin. Hypertens., 2003, 5(1), 53-57. doi: 10.1111/j.1524-6175.2003.00514.x PMID: 12556654
  20. Carpio-Rivera, E.; Moncada-Jiménez, J.; Salazar-Rojas, W.; Solera-Herrera, A. Acute effects of exercise on blood pressure: A meta-analytic investigation. Arq. Bras. Cardiol., 2016, 106(5), 422-433. doi: 10.5935/abc.20160064 PMID: 27168471
  21. Smart, N.A.; Gow, J.; Bleile, B.; Van der Touw, T.; Pearson, M.J. An evidence-based analysis of managing hypertension with isometric resistance exercise-are the guidelines current? Hypertens. Res., 2020, 43(4), 249-254. doi: 10.1038/s41440-019-0360-1 PMID: 31758166
  22. Liu, M.Y.; Li, N.; Li, W.A.; Khan, H. Association between psychosocial stress and hypertension: A systematic review and meta-analysis. Neurol. Res., 2017, 39(6), 573-580. doi: 10.1080/01616412.2017.1317904 PMID: 28415916
  23. Vučević, D.; Jorgačević, B.; Radosavljević, M.; Đorđević, D.; Radak, Đ. Risk factors for atherosclerosis in the light of existing scientific facts. Medicinska Istraživanja, 2017, 51(3), 7-19.
  24. Rimoldi, S.F.; Scherrer, U.; Messerli, F.H. Secondary arterial hypertension: when, who, and how to screen? Eur. Heart J., 2014, 35(19), 1245-1254. doi: 10.1093/eurheartj/eht534 PMID: 24366917
  25. Vučević, D.; Jorgačević, B.; Radosavljević, T.; Radak, Đ.; Kovačević, D. The relationship between insulin resistance and cardiovascular system disorders. Medicinska Istraživanja, 2015, 49(3), 5-15.
  26. Yildiz, M.; Oktay, A.A.; Stewart, M.H.; Milani, R.V.; Ventura, H.O.; Lavie, C.J. Left ventricular hypertrophy and hypertension. Prog. Cardiovasc. Dis., 2020, 63(1), 10-21. doi: 10.1016/j.pcad.2019.11.009 PMID: 31759953
  27. Cordonnier, C.; Demchuk, A.; Ziai, W.; Anderson, C.S. Intracerebral haemorrhage: Current approaches to acute management. Lancet, 2018, 392(10154), 1257-1268. doi: 10.1016/S0140-6736(18)31878-6 PMID: 30319113
  28. Supiano, M.A.; Williamson, J.D. New guidelines and sprint results. Circulation, 2019, 140(12), 976-978. doi: 10.1161/CIRCULATIONAHA.119.037872 PMID: 31525101
  29. Seccia, T.M.; Caroccia, B.; Calò, L.A. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J. Hypertens., 2017, 35(2), 205-212. doi: 10.1097/HJH.0000000000001170 PMID: 27782909
  30. Khoynezhad, A.; Plestis, K. A. Managing emergency hypertension in aortic dissection and aortic aneurysm surgery. J. Card. Surg, 2006, 21(1), 3-7. doi: 10.1111/j.1540-8191.2006.00213.x
  31. Radenković, M.; Stojanović, M.; Prostran, M. Novel facts in pharmacology of endothelial dysfunction. Medicinska Istraživanja, 2015, 49(3), 18-22.
  32. Karakayali, M.; Omar, T.; Artac, I.; Rencuzogullari, İ.; Karabag, Y.; Demir, O. The relationship between the systemic immune-inflammation index and reverse-dipper circadian pattern in newly diagnosed hypertensive patients. J. Clin. Hypertens., 2023, 25(8), 700-707. doi: 10.1111/jch.14688 PMID: 37464585
  33. Edvardsson, B. Hypertensive encephalopathy and cerebral infarction. Springerplus, 2014, 3(1), 741. doi: 10.1186/2193-1801-3-741 PMID: 25932363
  34. Zuber, S.M.; Kantorovich, V.; Pacak, K. Hypertension in pheochromocytoma: Characteristics and treatment. Endocrinol. Metab. Clin. North Am., 2011, 40(2), 295-311. doi: 10.1016/j.ecl.2011.02.002 PMID: 21565668
  35. Fu, J.; Liu, Y.; Zhang, L.; Zhou, L.; Li, D.; Quan, H.; Zhu, L.; Hu, F.; Li, X.; Meng, S.; Yan, R.; Zhao, S.; Onwuka, J.U.; Yang, B.; Sun, D.; Zhao, Y. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J. Am. Heart Assoc., 2020, 9(19), e016804. doi: 10.1161/JAHA.120.016804 PMID: 32975166
  36. Kaminsky, L.A.; German, C.; Imboden, M.; Ozemek, C.; Peterman, J.E.; Brubaker, P.H. The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. Prog. Cardiovasc. Dis., 2022, 70, 8-15. doi: 10.1016/j.pcad.2021.12.001 PMID: 34922952
  37. Mattavelli, E.; Catapano, A.L.; Baragetti, A. Molecular immune-inflammatory connections between dietary fats and atherosclerotic cardiovascular disease: Which translation into clinics? Nutrients, 2021, 13(11), 3768. doi: 10.3390/nu13113768 PMID: 34836026
  38. Dan, X.; Mushi, Z.; Baili, W.; Han, L.; Enqi, W.; Huanhu, Z.; Shuchun, L. Differential analysis of hypertension-associated intestinal microbiota. Int. J. Med. Sci., 2019, 16(6), 872-881. doi: 10.7150/ijms.29322 PMID: 31337961
  39. Sidhu, S.K.; Weavil, J.C.; Rossman, M.J.; Jessop, J.E.; Bledsoe, A.D.; Buys, M.J.; Supiano, M.S.; Richardson, R.S.; Amann, M. Exercise pressor reflex contributes to the cardiovascular abnormalities characterizing. Hypertension, 2019, 74(6), 1468-1475. doi: 10.1161/HYPERTENSIONAHA.119.13366 PMID: 31607174
  40. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.; Coca, A.; De Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.; Shlyakhto, E.; Tsioufis, K.; Aboyans, V.; Desormais, I. 2018 Practice guidelines for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. Blood Press., 2018, 27(6), 314-340. doi: 10.1080/08037051.2018.1527177 PMID: 30380928
  41. Sheppard, J.P.; Stevens, S.; Stevens, R.; Martin, U.; Mant, J.; Hobbs, F.D.R.; McManus, R.J. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern. Med., 2018, 178(12), 1626-1634. doi: 10.1001/jamainternmed.2018.4684 PMID: 30383082
  42. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr; Roccella, E.J. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 2003, 42(6), 1206-1252. doi: 10.1161/01.HYP.0000107251.49515.c2 PMID: 14656957
  43. Messerli, F.H.; Bangalore, S.; Bavishi, C.; Rimoldi, S.F. Angiotensin-converting enzyme inhibitors in hypertension. J. Am. Coll. Cardiol., 2018, 71(13), 1474-1482. doi: 10.1016/j.jacc.2018.01.058 PMID: 29598869
  44. Vučević, D.; Jorgačević, B.; Đorđević, D.; Radak, Đ.; Radosavljević, M.; Lalić, D. Diabetic vascular disease: Cellular and molecular approach. Medicinska istraživanja, 2017, 51(1), 18-28.
  45. Radenkovic, M.; Stojanović, M.; Nešić, I.; Prostran, M. Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications. Indian J. Med. Res., 2016, 144(2), 154-168. doi: 10.4103/0971-5916.195022 PMID: 27934794
  46. Gallo, G.; Volpe, M.; Rubattu, S. Angiotensin receptor blockers in the management of hypertension: A real-world perspective and current recommendations. Vasc. Health Risk Manag., 2022, 18, 507-515. doi: 10.2147/VHRM.S337640 PMID: 35846737
  47. Rakugi, H.; Kario, K.; Yamaguchi, M.; Sasajima, T.; Gotou, H.; Zhang, J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: A randomized, double-blind, multicenter study. Hypertens. Res., 2022, 45(5), 824-833. doi: 10.1038/s41440-021-00819-7 PMID: 35058583
  48. Radenković, M.; Stojanović, M.; Prostran, M. Calcium channel blockers in restoration of endothelial function: systematic review and meta-analysis of randomized controlled trials. Curr. Med. Chem., 2019, 26(29), 5579-5595. doi: 10.2174/0929867325666180713144806 PMID: 30009701
  49. World Health Organization. Guideline for the Pharmacological Treatment of Hypertension in Adults; World Health Organization: Genève, Switzerland, 2021, 48. https://www.who.int/publications/i/item/978924003- 3986
  50. Roush, G.C.; Sica, D.A. Diuretics for hypertension: A review and update. Am. J. Hypertens., 2016, 29(10), 1130-1137. doi: 10.1093/ajh/hpw030 PMID: 27048970
  51. Mishra, S. Diuretics in primary hypertension – Reloaded. Indian Heart J., 2016, 68(5), 720-723. doi: 10.1016/j.ihj.2016.08.013 PMID: 27773415
  52. Jo, W.; Koh, E.S.; Chung, S. Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease. Clin. Hypertens., 2023, 29(1), 14. doi: 10.1186/s40885-023-00238-5 PMID: 37183259
  53. Ruiz-Hurtado, G.; Banegas, J.R.; Sarafidis, P.A.; Volpe, M.; Williams, B.; Ruilope, L.M. Has the sprint trial introduced a new blood-pressure goal in hypertension? Nat. Rev. Cardiol., 2017, 14(9), 560-565. doi: 10.1038/nrcardio.2017.74 PMID: 28492286
  54. Liew, D.; Krum, H. Aldosterone receptor antagonists for hypertension: What do they offer? Drugs, 2003, 63(19), 1963-1972. doi: 10.2165/00003495-200363190-00001 PMID: 12962513
  55. Maron, B.A.; Leopold, J.A. Aldosterone receptor antagonists: Effective but often forgotten. Circulation, 2010, 121(7), 934-939. doi: 10.1161/CIRCULATIONAHA.109.895235 PMID: 20177008
  56. Guichard, J.L.; Clark, D., III; Calhoun, D.A.; Ahmed, M.I. Aldosterone receptor antagonists: Current perspectives and therapies. Vasc. Health Risk Manag., 2013, 9, 321-331. PMID: 23836977
  57. Wei, F.F.; Zhang, Z.Y.; Huang, Q.F.; Staessen, J.A. Diagnosis and management of resistant hypertension: State of the art. Nat. Rev. Nephrol., 2018, 14(7), 428-441. doi: 10.1038/s41581-018-0006-6 PMID: 29700488
  58. Prichard, B.N.C.; Cruickshank, J.M.; Graham, B.R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press., 2001, 10(5-6), 366-386. doi: 10.1080/080370501753400665 PMID: 11822540
  59. Fowler, M.B. Hypertension, heart failure, and beta-adrenergic blocking drugs. J. Am. Coll. Cardiol., 2008, 52(13), 1073-1075. doi: 10.1016/j.jacc.2008.06.032 PMID: 18848140
  60. Paštrović, F.; Okštajner, P.K.; Vodanović, M.; Raos, D.; Jug, J.; Lovrić Benčić, M.; Prkačin, I. The role of anxiolytics in hypertensive urgency management. Psychiatr. Danub., 2020, 32(4), 593-596. PMID: 33212468
  61. Radosavljevic, M.; Svob Strac, D.; Jancic, J.; Samardzic, J. The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes, 2023, 14(5), 1095. doi: 10.3390/genes14051095 PMID: 37239455
  62. Rahman, F.; Muthaiah, N.; Kumaramanickavel, G. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension. Indian J. Pharmacol., 2021, 53(4), 301-309. PMID: 34414909
  63. Lee, S.H.; Park, K.K.; Mah, S.Y.; Chung, B.H. Effects of α-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer Prostatic Dis., 2010, 13(4), 333-337. doi: 10.1038/pcan.2010.19 PMID: 20567256
  64. Tziomalos, K.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc. Med. J., 2011, 5(1), 85-89. doi: 10.2174/1874192401105010085 PMID: 21769302
  65. van de Vusse, D.; Mian, P.; Schoenmakers, S.; Flint, R.B.; Visser, W.; Allegaert, K.; Versmissen, J. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: A systematic review. Eur. J. Clin. Pharmacol., 2022, 78(11), 1763-1776. doi: 10.1007/s00228-022-03382-3 PMID: 36104450
  66. Acelajado, M.C.; Hughes, Z.H.; Oparil, S.; Calhoun, D.A. Treatment of resistant and refractory hypertension. Circ. Res., 2019, 124(7), 1061-1070. doi: 10.1161/CIRCRESAHA.118.312156 PMID: 30920924
  67. Shamon, S.D.; Perez, M.I. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Libr., 2016, 2016(12), CD007655. doi: 10.1002/14651858.CD007655.pub3 PMID: 27997978
  68. Sica, D.A. Minoxidil: An underused vasodilator for resistant or severe hypertension. J. Clin. Hypertens., 2004, 6(5), 283-287. doi: 10.1111/j.1524-6175.2004.03585.x PMID: 15133413
  69. Di Daniele, N.; De Francesco, M.; Violo, L.; Spinelli, A.; Simonetti, G. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol. Dial. Transplant., 2012, 27(4), 1689-1690. doi: 10.1093/ndt/gfs044 PMID: 22467751
  70. Ipek, E.; Oktay, A.A.; Krim, S.R. Hypertensive crisis. Curr. Opin. Cardiol., 2017, 32(4), 397-406. doi: 10.1097/HCO.0000000000000398 PMID: 28306673
  71. Patel, K.K.; Young, L.; Howell, E.H.; Hu, B.; Rutecki, G.; Thomas, G.; Rothberg, M.B. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JAMA Intern. Med., 2016, 176(7), 981-988. doi: 10.1001/jamainternmed.2016.1509 PMID: 27294333
  72. Peixoto, A.J. Acute severe hypertension. N. Engl. J. Med., 2019, 381(19), 1843-1852. doi: 10.1056/NEJMcp1901117 PMID: 31693807
  73. Paini, A.; Aggiusti, C.; Bertacchini, F.; Agabiti Rosei, C.; Maruelli, G.; Arnoldi, C.; Cappellini, S.; Muiesan, M.L.; Salvetti, M. Definitions and epidemiological aspects of hypertensive urgencies and emergencies. High Blood Press. Cardiovasc. Prev., 2018, 25(3), 241-244. doi: 10.1007/s40292-018-0263-2 PMID: 29916180
  74. Kulkarni, S.; Glover, M.; Kapil, V.; Abrams, S.M.L.; Partridge, S.; McCormack, T.; Sever, P.; Delles, C.; Wilkinson, I.B. Management of hypertensive crisis: british and irish hypertension society position document. J. Hum. Hypertens., 2022, 37(10), 863-879. doi: 10.1038/s41371-022-00776-9 PMID: 36418425
  75. Tisdale, J.E.; Huang, M.B.; Borzak, S. Risk factors for hypertensive crisis: Importance of out-patient blood pressure control. Fam. Pract., 2004, 21(4), 420-424. doi: 10.1093/fampra/cmh412 PMID: 15249531

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024